Core Viewpoint - Gene delivery is a critical component in life sciences research and gene therapy, acting as a "bridge" to deliver nucleic acids into cells for gene expression, knockdown, or editing, despite facing numerous challenges over time [3]. Group 1: Challenges in Traditional Gene Delivery Tools - Traditional tools for gene delivery, such as liposomes, viral vectors, and electroporation, have significant limitations, including low efficiency in primary immune cells and stem cells, high mutation risks, and potential damage to cell membranes [4][7]. Group 2: Innovative Solutions - Westlake University and the Westlake Condensate team have developed the ProteanFect gene delivery system, a novel non-viral, non-liposomal, and non-electroporation delivery method that mimics endogenous protein liquid-liquid phase separation for efficient nucleic acid encapsulation and delivery [6]. Group 3: Research Breakthroughs Enabled by ProteanFect - ProteanFect has supported multiple key research breakthroughs, including: 1. Immune cell function studies published in *Nature Cell Biology* and *Nature Microbiology*, demonstrating the system's ability to deliver siRNA to mouse primary T cells [9]. 2. Gene editing and metabolic validation studies published in *Signal Transduction and Targeted Therapy* and *Nature Communications*, showcasing efficient gene knockout in T cells [10]. 3. Exploration of special cell mechanisms published in *Nature Genetics* and *Journal of Advanced Research*, revealing insights into mitochondrial function and lymphocyte activity [11]. Group 4: Global Recognition and Impact - The scientific value of ProteanFect has been recognized internationally, with its technology selected for presentations at major conferences, including the American Society of Hematology and the International Society for Stem Cell Research [14]. The strategic partnership with OriGene marks its entry into the global mainstream research reagent supply system [14]. Group 5: Advantages of ProteanFect - ProteanFect offers three core advantages: 1. Superior delivery efficiency, especially in hard-to-transfect cell models, ensuring experimental precision [17]. 2. Lower cytotoxicity, preserving cell viability and natural function, which enhances data reliability [17]. 3. User-friendly convenience, with a straightforward protocol that reduces experimental time and increases reproducibility [17]. Group 6: Future Prospects - The development of ProteanFect is just the beginning, with ongoing exploration of its potential across various nucleic acid types and complex models, moving towards a new phase of gene delivery that aligns more closely with biological realities [19].